Kronos Bio

Roche acquires Poseida Therapeutics for up to $1.5B, expanding into CAR-T therapies. U.S. overdose deaths decline by 14.5% to 97,000 over 12 months. Arrowhead Pharmaceuticals licenses programs to Sarepta Therapeutics for $500M upfront and $325M in equity. Recordati and Angelini Pharma consider merger to form Europe's largest generics group. FDA approves BridgeBio's heart drug for transthyretin amyloidosis, challenging Pfizer's tafamidis. Novo Holdings expected to receive EU approval for $16.5B acquisition of Catalent Pharma Solutions. Amgen's obesity drug MariTide shows 20% weight loss in Phase II. Anavex Life Sciences submits MAA to EMA for Alzheimer's treatment. Biohaven's muscle drug fails in SMA study. embecta reports strong revenues of $1.12B, discontinues insulin patch pump. Axsome Therapeutics reports positive Phase 3 results for narcolepsy drug AXS-12. Kronos Bio to lay off 83% of workforce. PTC Therapeutics sells Rare Pediatric Disease Priority Review Voucher for $150M. EMA launches medicine shortages monitoring platform. Alector lays off 41 employees after Alzheimer's drug AL002 fails. Grifols seeks to refinance €1.4B in debt. Roche's cancer drug tiragolumab fails Phase 3 trial.

Kronos Bio to lay off 83% of workforce, CEO steps down; Idorsia in talks to sell blood pressure drug rights for $35M; PTC Therapeutics shelves failed ALS drug, plans to sell review voucher for $150M; Acadia Pharmaceuticals acquires global rights to Saniona's experimental medicine; Soleno Therapeutics' FDA decision on Prader-Wili syndrome drug delayed to March 2025; Alnylam Pharmaceuticals awaits FDA decision on ATTR-CM drug by March 23.

Kronos Bio discontinues istisociclib development due to safety concerns, plans strategic alternatives to maximize shareholder value, and explores partnerships for preclinical assets KB-9558 and KB-7898.

Kronos Bio’s KB-7898, an investigational therapy for Sjögren’s disease, reduced antibody and inflammatory molecule production in preclinical studies. The therapy targets p300, a factor in antibody production, and may impact Sjögren’s etiology. Kronos plans further preclinical studies to assess safety and pharmacological properties, potentially leading to a clinical trial.

Kronos Bio announces KB-7898, a p300 KAT inhibitor for Sjögren’s disease, with plans to initiate IND-enabling studies in Q4 2024. Preclinical data will be presented at ACR Convergence 2024, showing KB-7898's potential to reduce antibody and cytokine production, impacting the disease's etiology.

DelveInsight's 'Relapsed/refractory acute myeloid leukemia (AML) Pipeline Insight 2024' covers 50+ companies and 75+ pipeline drugs, including clinical and nonclinical stage products, with therapeutic assessments by product type, stage, route of administration, and molecule type. Key companies and therapies highlighted.